Skip to main content
. 2022 Feb 23;13:799988. doi: 10.3389/fimmu.2022.799988

Figure 3.

Figure 3

Association of HER2 mutation with tumor features validated in independent stomach adenocarcinoma (STAD) cohorts. (A) Incidences of HER2 alterations in ACRG and AHJU. (B) Association of HER2 mutation with microsatellite instability (MSI), tumor mutation burden (TMB), and tumor neoantigen burden (TNB). (C) Multiple-immunofluorescence staining of surface biomarkers of immune cells in STAD tissues. 1: CD8 staining; 2: CD56 staining; 3: CD68 (green) and HLA-DR (red) staining; 4: the reconstructed image for all surface biomarkers. (D) The density of infiltrating immune cells in tumor parenchyma stratified by HER2 mutation status. ACRG, Asian Cancer Research Group; AHJU, Affiliated Hospital of Jiangsu University; AMPL, amplification; Mut, mutation; WT, wild-type.